At the time of writing, Dianthus Therapeutics Inc [DNTH] stock is trading at $44.09, up 0.94%. An important factor to consider is whether the stock is rising or falling in short-term value. The DNTH shares have gain 8.01% over the last week, with a monthly amount glided 31.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dianthus Therapeutics Inc [NASDAQ: DNTH] stock has seen the most recent analyst activity on October 14, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $56. On December 20, 2024, TD Cowen initiated with a Buy rating. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $48 on October 03, 2024. Robert W. Baird initiated its recommendation with an Outperform and recommended $58 as its price target on July 26, 2024. In a note dated May 16, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $40 on this stock.
For the past year, the stock price of Dianthus Therapeutics Inc fluctuated between $13.36 and $44.21. Currently, Wall Street analysts expect the stock to reach $67.25 within the next 12 months. Dianthus Therapeutics Inc [NASDAQ: DNTH] shares were valued at $44.09 at the most recent close of the market. An investor can expect a potential return of 52.53% based on the average DNTH price forecast.
Analyzing the DNTH fundamentals
According to Dianthus Therapeutics Inc [NASDAQ:DNTH], the company’s sales were 3.08M for trailing twelve months, which represents an -81.77% plunge. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -45.58%, Pretax Profit Margin comes in at -41.05%, and Net Profit Margin reading is -41.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.33 and Total Capital is -0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 43.37 points at the first support level, and at 42.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.64, and for the 2nd resistance point, it is at 45.18.
Ratios To Look Out For
It is important to note that Dianthus Therapeutics Inc [NASDAQ:DNTH] has a current ratio of 17.35. On the other hand, the Quick Ratio is 17.35, and the Cash Ratio is 2.35. Considering the valuation of this stock, the price to sales ratio is 613.77, the price to book ratio is 3.46.
Transactions by insiders
Recent insider trading involved Randhawa Simrat, EVP, Head of R&D, that happened on Nov 14 ’25 when 0.11 million shares were sold. EVP, Head of R&D, Randhawa Simrat completed a deal on Nov 13 ’25 to sell 87507.0 shares. Meanwhile, Officer SIMRAT RANDHAWA bought 0.2 million shares on Nov 13 ’25.
